Actively Recruiting

Phase Not Applicable
Age: 22Years +
FEMALE
NCT04248283

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Led by Uromedica · Updated on 2024-07-23

167

Participants Needed

2

Research Sites

257 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.

CONDITIONS

Official Title

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Who Can Participate

Age: 22Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female at least 22 years old
  • Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency
  • Provocative pad weight greater than 11.0 grams
  • Candidate for surgical intervention
  • Negative urinalysis
  • Normal cystourethroscopy
  • Failed at least 6 months of previous treatment(s) for stress urinary incontinence
  • Willing and able to sign informed consent and comply with trial follow-up requirements
Not Eligible

You will not qualify if you...

  • Pregnant or lactating
  • Life expectancy less than 5 years
  • Uncontrolled diabetes (HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL)
  • Auto-immune disease
  • Undergoing radiation therapy
  • Active urinary tract infection
  • Detrusor instability refractory to medication
  • Reduced bladder compliance by cystometrogram
  • Significant residual urine volume (>100 ml) with weak detrusor contraction at bladder volume 250 ml
  • Has, had, or suspected bladder cancer
  • History of bladder stones
  • Urethral stricture seen during cystourethroscopy
  • Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
  • Diathesis, hemophilia, or bleeding disorder
  • Rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse grade 3 or higher
  • Prior pelvic radiotherapy
  • Prior artificial urinary sphincter implant
  • Neurogenic condition affecting bladder/sphincter function

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Colorado

Denver, Colorado, United States, 80045

Actively Recruiting

2

CHI Health Research Center

Omaha, Nebraska, United States, 68124

Actively Recruiting

Loading map...

Research Team

P

Patrick Gora

CONTACT

T

Timothy C Cook, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI | DecenTrialz